Koichi Matsuda
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
デスモイド型線維腫症の病態に基づく診断、新規治療開発への学際的・国際的共同研究
Open Date: 2017-04-01
Close Date: 2021-03-31
Grant: Close
難治性希少肉腫である淡明細胞肉腫の治療標的となるゲノム異常の探索
Open Date: 2017-04-01
Close Date: 2020-03-31
Grant: Close
The development of treatment and the elucidation of the characteristics of tumor cells by exhaustive analysis of the p53 regulatory pathway
Open Date: 2016-04-01
Close Date: 2018-03-31
Grant: Close
Search of the fusion gene with the aim of re-construction of the identification and tumor concept of diagnostic markers in bone soft tissue tumor
Open Date: 2016-04-01
Close Date: 2021-03-31
Grant: Close
p53制御経路の網羅的解析による腫瘍細胞の特性の解明と治療法の開発
Open Date: 2016-04-01
Close Date: 2018-03-31
Articles (16)
Year:
2026
Aortic stenosis (AS) is a common valvular heart disease and has no pharmacological therapies. We performed a multi-ancestry genome-wide association meta-analysis of 86,864 AS cases among 2,853,408 individuals, discovering 241 autosomal independent risk loci and 3 X chromosome risk loci. We additionally performed sex-stratified and ancestry-stratified genome-wide association studies (GWASs), identifying an additional 5 sex-specific risk loci, 11 risk loci in European ancestry individuals and 1 risk locus in African ancestry individuals. We also performed a transcriptome-wide association study using expression quantitative trait loci from human aortic valves, discovering 54 new genes for which genetically predicted expression influences the risk of AS. We then generated a new polygenic risk score for AS. Finally, we performed gene silencing experiments targeting biologically relevant genes identified by our GWAS. Silencing of CMKLR1 and LTBP4 in human valvular interstitial cells substantially decreased mineralization, implicating a role for polyunsaturated fatty acids and transforming growth factor β signaling in AS.
Year:
2026
BRCA1 pathogenic variants are associated with a lower risk of developing prostate cancer than BRCA2, but aggressiveness remains unclear. Therefore, screening criteria are insufficiently established. Here, we reanalyzed the impact of BRCA1 pathogenic variants on aggressiveness using 11 300 prostate cancer patients, adjusting for age and area. The proportion of aggressive prostate cancer was higher in BRCA1 carriers (86.7%) than in noncarriers (61.1%) (odds ratio = 4.87; 95% confidence interval = 1.05 to 22.60). The proportion of high prostate-specific antigen levels was higher in BRCA1 carriers (66.7%) than in noncarriers (27.9%) (P = 7.61 × 10−3). BRCA1 carriers had a worse tendency than noncarriers for T classification (T3–4: BRCA1, 36.4%; noncarriers, 23.2%) and Gleason score (GS8–10: BRCA1, 53.3%; noncarriers, 31.0%). Moreover, we observed the first case of BRCA1-related aggressive prostate cancer showing long-term survival through early detection and multidisciplinary treatment. These results suggest that recommendations for early prostate cancer screening might need to be reconsidered for BRCA1 carriers.
Year:
2026
Clonal hematopoiesis of indeterminate potential (CHIP) has broad clinical relevance, and TP53 plays various roles within cells. However, the gene-specific and cross-disease significance of CHIP with TP53 mutations (TP53-CHIP) remains unclear. In this study, we evaluated TP53-CHIP using targeted sequencing data of 140,597 individuals without hematologic neoplasms in BioBank Japan. We identified 1,157 individuals with TP53-CHIP and clarified the characteristics of mutations and carriers. TP53-CHIP was associated with poor overall survival, especially because of lymphoid neoplasms and respiratory disease, in addition to myeloid neoplasms. Significant interactions accompanied by excess risks were observed between TP53-CHIP and lifestyle factors for disease-specific mortality: acetaldehyde exposure (resulting from the interaction between drinking and the germline variant of ALDH2) for myeloid neoplasms and smoking for respiratory disease. The clinical significance of TP53-CHIP was sometimes largely independent of variant allele fractions. These findings elucidate aspects of disease pathogenesis and inform personalized risk management. Significance: TP53-CHIP contributed to a wide range of outcomes besides myeloid neoplasm mortality. TP53-CHIP, when combined with environmental factors, showed a remarkably higher risk for disease-specific mortality, accompanied by excess risks.
Year:
2025
Frequencies of all reported germline CHEK2 variant carriers and carriers of variants concordantly categorized by functional our kinase assays in breast cancer patients and controls in 12 analyzed population datasets.
Year:
2025
Clonal hematopoiesis of indeterminate potential (CHIP) has broad clinical relevance, and TP53 plays various roles within cells. However, the gene-specific and cross-disease significance of CHIP with TP53 mutations ( TP53 -CHIP) remains unclear. In this study, we evaluated TP53 -CHIP using targeted sequencing data of 140,597 individuals without hematologic neoplasms in BioBank Japan. We identified 1,157 individuals with TP53 -CHIP and clarified the characteristics of mutations and carriers. TP53 -CHIP was associated with poor overall survival, especially because of lymphoid neoplasms and respiratory disease, in addition to myeloid neoplasms. Significant interactions accompanied by excess risks were observed between TP53 -CHIP and lifestyle factors for disease-specific mortality: acetaldehyde exposure (resulting from the interaction between drinking and the germline variant of ALDH2 ) for myeloid neoplasms and smoking for respiratory disease. The clinical significance of TP53 -CHIP was sometimes largely independent of variant allele fractions. These findings elucidate aspects of disease pathogenesis and inform personalized risk management. Significance: TP53 -CHIP contributed to a wide range of outcomes besides myeloid neoplasm mortality. TP53 -CHIP, when combined with environmental factors, showed a remarkably higher risk for disease-specific mortality, accompanied by excess risks.
Year:
2025
Clinical impact of TP53 -CHIP. A , TP53 -CHIP risk of mortality overall and across major disease categories (number of events: cardiovascular disease, 5,645; non-hematologic neoplasms, 13,256; nonneoplastic respiratory disease, 3,405; lymphoid neoplasms, 199; myeloid neoplasms, 162; and overall, 29,626). B, Sub-analysis of cardiovascular diseases (number of events: ischemic heart disease, 1,630; stroke, 1,649). C, Sub-analysis of non-hematologic neoplasms (number of events: liver cancer, 1,718; pancreatic cancer, 929; colorectal cancer, 1,897; gastric cancer, 1,751; breast cancer, 832; prostate cancer, 770; lung cancer, 2,833; and esophageal cancer, 593). D, Sub-analysis of nonneoplastic respiratory diseases (number of events: respiratory tract infection, 1,892; chronic lower respiratory tract disease, 440; and interstitial pneumonia, 410) are shown. HRs and their 95% CIs were estimated using Cox proportional hazards models of disease-specific mortality adjusted for age, sex, drinking habits, alcohol consumption, smoking habits, Brinkman index, body mass index, and comorbidities (hyperlipidemia, hypertension, diabetes, and cancer). All results among other models are shown in Supplementary Table S5. *, q q q
Year:
2025
Impact of smoking and TP53 -CHIP on respiratory disease mortality. A, The cause-specific survival from respiratory disease (nonneoplastic respiratory disease and lung cancer) was estimated using the Kaplan–Meier method. Smoking status was defined as ever smoker. B, HRs and their 95% CIs were estimated using Cox proportional hazards models of respiratory disease mortality adjusted for age, sex, drinking habits, alcohol consumption, Brinkman index, body mass index, and comorbidities (hyperlipidemia, hypertension, diabetes, and cancer).
Year:
2025
Mutation patterns and hotspot locations of TP53 -CHIP. A, Mutation patterns of CHIP in this study (1,198 mutations) and somatic mutations in the NCI TP53 database (RRID: SCR_026878; 28,310 mutations). B, Mutations that 10 or more individuals with TP53 -CHIP carry in this study are shown. The vertical axis represents the number of carriers. Detailed information of mutations is provided in Supplementary Table S2. C, Codon of the hotspot mutation, which accounted for more than 1% of all mutations, in the NCI TP53 database (RRID: SCR_026878). The vertical axis represents the proportion of mutations at each codon. Indel, insertion or deletion.
Year:
2025
Impact of acetaldehyde and TP53 -CHIP on myeloid neoplasm mortality. A, The cause-specific survival from myeloid neoplasms was estimated using the Kaplan–Meier method. Individuals prone to acetaldehyde exposure were defined as individuals with both rs671 Lys+ and ever-drinker status. B, HRs and their 95% CIs were estimated using Cox proportional hazards models of myeloid neoplasm mortality adjusted for age, sex, drinking habits, alcohol consumption, smoking habits, Brinkman index, body mass index, comorbidities (hyperlipidemia, hypertension, diabetes, and cancer), and ALDH2 . AcAld, acetaldehyde.
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Collaborators (66)
Kyuto Sonehara
Associate Professor
University of Tsukuba
Tomáš Zima
Head of Institute
Charles University and General University Hospital in Prague, First Faculty of Medicine
Kathleen Claes
Full professor
Ghent University Hospital
Giuseppe Matullo
-
Andrea Ganna
Professor at University of Helsinki
University of Helsinki
Lisa Wiesmüller
Professor
Ulm University
Christopher A. Haiman
University of Southern California
Christine Ambrosone
Roswell Park Comprehensive Cancer Center
Radoslaw Debiec
NIHR Academic Clinical Lecturer in Platform Science
University of Leicester
Eric Hahnen
-
Susan Domchek
Professor, Clinician-Educator
University of Pennsylvania
Sara Lindström
University of Washington
Maria Rossing
Associate Clinical Professor
Copenhagen University Hospital
Marco Montagna
Istituto Oncologico Veneto
Katherine Nathanson
Professor
University of Pennsylvania
Nicoletta Resta
Full Professor Medical Genetics
University of Bari Aldo Moro
Song Yao
Professor
Roswell Park Comprehensive Cancer Center
Maria Piane
Sapienza University of Rome
Sara González
Institut Català d'Oncologia
Yasuo Takahashi
Professor
Nihon University School of Medicine
FEI CHEN
Assistant Professor
University of Southern California
Ruth Loos
The Charles Bronfman Professor in Personalized Medicine
Københavns Universitet
J. Gustav Smith
-
Chikashi Terao
RIKEN
Takeshi Suzuki
Kanazawa University
Alexandra Martins
INSERM
Julie R Palmer
Boston University School of Medicine
Alexander E Volk
-
Peter Kraft
Professor
Harvard T.H. Chan School of Public Health
Siddhartha Yadav
Associate Professor of Oncology
Mayo Clinic
Mariarosaria Calvello
European Institute of Oncology
anna coppa
Sapienza University of Rome
Allison DePersia
NorthShore University HealthSystem
Kazuyoshi Ishigaki
Professor
Keio University
Carlo Maj
Head of Bioinformatics | Research Group Leader – Genetic Epidemiology
University of Marburg
Paul James
Head of Adult Genetics
The Royal Melbourne Hospital Royal Park Campus
Florentia Fostira
National Centre for Scientific Research-Demokritos
Paolo Radice
Head of Reserach Unit
Fondazione IRCCS Istituto Nazionale dei Tumori
Maria Elena. Martinez
University of California
Marketa Janatova
Assistanf Professor and researcher
Přírodovědecká Fakulta, Univerzita Karlova
Quinn Wells
Associate Professor of Medicine
Vanderbilt University Medical Center
Eric Farber-Eger
Vanderbilt University Medical Center
Gareth Evans
The University of Manchester
Weng Khong Lim
Assistant Professor
Duke-NUS Medical School
Barbara Pasini
Associate Professor of Medical Genetics
Università degli Studi di Torino
Ian Campbell
Group Leader
Peter MacCallum Cancer Institute
Yoichiro Kamatani
Professor
University of Tokyo
Stacey J. Winham
Mayo Clinic College of Medicine and Science
Jeffrey Weitzel
Professor and Director
University of Kansas Cancer Center
Banu K. Arun
The University of Texas MD Anderson Cancer Center
Paul Auer
Professor
Medical College of Wisconsin
Saori Sakaue
University of Washington
Ken Suzuki
Osaka University
Sébastien Thériault
Associate Professor
Laval University
Alvaro Monteiro
Senior Member - Full Professor
H Lee Moffitt Cancer Center and Research Institute
Corinna Ernst
Hannover Medical School
Ole Birger Pedersen
Professor
Zealand University Hospital
Peter W. F. Wilson
-
Kathryn Ruddy
Professor
Mayo Clinic
Keiko Yamazaki
Lecturer
Chiba University Graduate School of Medicine
Lidia Feliubadaló
Institut Català d'Oncologia
Joanne Ngeow
Head
Nanyang Technological University (NTU)
Zdenek Kleibl
Laboratory of oncogenetics (head)
Charles University, First Faculty of Medicine
Nicholas Boddicker
Research Associate
Mayo Clinic
Amanda Toland
Ohio State University
Laura Cortesi
University of Modena and Reggio Emilia
Make your next move.
Prepare your application
Review drafts before you send them.